IP Library › Granted Patent US 12,378,289
Granted Patent B2
US 12,378,289 · App. 16/626,019 · Granted Aug 5, 2025

Recombinant oncolytic viruses for treatment of metastatic cancers

Inventors: Roy Duncan (Mineville, CA); Chungen Pan (Guangzhou, CN)
Assignee: ENTOS PHARMACEUTICALS INC.
C07K14/005A61K35/765A61K35/766A61P35/04C12N7/00C07K2319/03C12N2720/12022C12N2720/12033C12N2760/20221C12N2760/20232
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,289
App. No.
16/626,019
Granted
Aug 5, 2025
Kind
B2
Abstract

Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.

Claims (5)

1. A method for treating breast, lung or colon cancer comprising administering to a subject in need thereof a composition consisting of (a) a recombinant oncolytic virus that expresses reovirus fusion-associated small transmembrane (FAST) proteins, wherein the FAST protein is a combination of p14/p15 comprising the ectodomain and transmembrane of p14 and the endodomain of p15; the ectodomain of p14, the transmembrane domain and endodomain of p15; or the ectodomain and endodomain of p14 and the transmembrane of p15, and (b) one or more pharmaceutically acceptable carriers or excipients.

2. The method of claim 1 , wherein the breast, lung or colon cancer is a metastatic breast, lung or colon cancer.

3. The method of claim 1 , wherein the FAST protein is p14 protein from reptilian reovirus; or a combination of p14 protein from reptilian reovirus and p15 protein from baboon reovirus.

4. The method of claim 3 , wherein the oncolytic virus is from herpesvirus, adenovirus, reovirus, measles virus, Newcastle disease virus, vaccina virus and vesicular stomatitis virus.

5. The method of claim 4 , wherein the oncolytic virus is vesicular stomatitis virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: DUNCAN, ROY; PAN, CHUNGEN
To: ENTOS PHARMACEUTICALS INC.
Reel/Frame 052145/0809 →
Priority Claims (1)
CA CA 2971832 · Jun 23, 2017 · national
Continuity (1)
Related Publication 20200123204A1 · Apr 23, 2020
References Cited (18)
US 7052832B2 · Coffey · 2006 [cited by examiner]
US 10603351B2 · Bell · 2020 [cited by examiner]
US 20110206640A1 · Bell et al. · 2011 [cited by applicant]
WO 20100250056A1 · 2010 [cited by examiner]
Brown et al. J Virol. Jan. 2009;83(2):552-61. doi: 10.1128/JVI.01921-08. Epub Oct. 29, 2008. [cited by examiner]
Wong Carmen et al. PLOS ONE, Mar. 17, 2016, pp. 1-18. [cited by examiner]
Brown et al. Journal of Virology, 2009, vol. 83, No. 2, pp. 552-561. [cited by examiner]
Top et al. PLOS Pathogens 2009, vol. 5, No. 3, pp. 1-14. [cited by examiner]
Salsman. J Virol, 2005, 79: 8090-8100. [cited by examiner]
Brown et al., The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis, J. Virol., 83(2):552-561 (2009). [cited by applicant]
Hastie et al., Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy aganist cancer, J. General. Virol., 93:2529-45 (2012). [cited by applicant]
Le Boeuf et al., Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models., Mol. Ther. Oncol., 6:80-9 (2017). [cited by applicant]
Maroun et al., Designing and building oncolytic viruses, Fut. Virol., 12(4):193-213 (2017). [cited by applicant]
Salsman et al., A Virus-Encoded Cell-Cell Fusion Machine Dependent on Surrogate Adhesins, PLOS Pathogens, 4(3):1-12 (2018). [cited by applicant]
International Search Report and Written Opinion of the International Search Authority, PCT/CA2018/050766, mailed Sep. 13, 2018. [cited by applicant]
Alkayyal et al., Oncolytic Rhabdo Virus MG 1-IL 12 Enhances Anti-tumour Immunity, Ottawa Hospital Research Institute Research Day, pp. 1-94, Nov. 2013. [cited by applicant]
Da Pan et al., Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis, [cited by applicant]
Wong et al., Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Mode… [cited by applicant]